research Steroid-Free Monotherapy with Tofacitinib in Severe Therapy-Resistant Alopecia: A Retrospective Analysis
Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
Search
for
Sort by
Research
990-1000 / 1000+ results 
research The Efficacy, Safety, and Recurrence Rate of Diphenylcyclopropenone Topical Immunotherapy for Alopecia Areata: A Systematic Review and Meta-Analysis
Diphenylcyclopropenone topical immunotherapy is effective for treating alopecia areata, with some side effects.
research And Next… Adnexa: Frontal Fibrosing Alopecia
A 55-year-old woman with several health conditions did not see hair regrowth after a transplant.
research A Review of Hormonal Therapy for Female Pattern (Androgenic) Alopecia
Hormonal therapy like cyproterone acetate and spironolactone may help female hair loss, but more research is needed, especially for pre-menopausal women.
research The Efficacy of Platelet-Rich Plasma Therapy in the Treatment of Androgenetic Alopecia: A Literature Review
PRP therapy is a promising and well-tolerated treatment for hair loss.
research Finasteride Treatment of Female Pattern Hair Loss
Finasteride with oral contraceptive helps improve hair loss in premenopausal women.
research Immune-Related Alopecia (Areata and Universalis) in Cancer Patients Receiving Immune Checkpoint Inhibitors
Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.
research Changes in Distribution Pattern of CD8 Lymphocytes in the Scalp in Alopecia Areata During Treatment With Diphenylcyclopropenone
Diphencyprone treatment increases CD8 lymphocytes in the scalp, which is associated with hair regrowth in alopecia areata patients.
research Cicatricial Alopecia: Overview and Treatment Recommendations
Permanent hair loss from cicatricial alopecia is treated by reducing inflammation and managing symptoms, but regrowth in scarred areas is unlikely.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.